DUNCAN BARBARA GAYLE — SEC Form 4 filings
SEC reporting owner CIK 1353128. 12 Form 4 filings on record with FilingPulse; latest filed 2026-06-23.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-02-26 to 2026-06-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 26.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | Director | 4 | — | — | 12 |
| HALOZYME THERAPEUTICS, INC. (HALO) | Director | 3 | — | — | 6 |
| Fusion Pharmaceuticals Inc. (FUSN) | Director | 1 | — | — | 4 |
| Ovid Therapeutics Inc. (OVID) | Director | 4 | — | — | 4 |
Form 4 filings — DUNCAN BARBARA GAYLE
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-23 | 4 | Atea Pharmaceuticals, Inc. (AVIR) | Option exercise (M): 29,600 @ $0 · Option exercise (M): 29,600 (derivative) @ $0 · Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 3,796 @ $0 · Grant/award (A): 6,040 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Ovid Therapeutics Inc. (OVID) | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Atea Pharmaceuticals, Inc. (AVIR) | Option exercise (M): 29,600 @ $0 · Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 · Option exercise (M): 29,600 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Ovid Therapeutics Inc. (OVID) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-05-02 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 4,165 @ $0 · Grant/award (A): 5,750 (derivative) @ $0 | EDGAR |
| 2024-12-16 | 4 | Ovid Therapeutics Inc. (OVID) | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Atea Pharmaceuticals, Inc. (AVIR) | Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Atea Pharmaceuticals, Inc. (AVIR) | Option exercise (M): 33,150 @ $0 · Option exercise (M): 33,150 (derivative) @ $0 | EDGAR |
| 2024-06-04 | 4 | Fusion Pharmaceuticals Inc. (FUSN) | Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) · Disposition to issuer (D): 17,000 (derivative) | EDGAR |
| 2024-04-29 | 4 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/award (A): 6,501 @ $0 · Grant/award (A): 8,804 (derivative) @ $0 | EDGAR |
| 2024-02-26 | 4 | Ovid Therapeutics Inc. (OVID) | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1353128 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →